These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12650801)

  • 1. Nonimmune complexed HCV RNA titer in serum as a predictor of interferon response in patients with chronic hepatitis C.
    Fujita N; Kaito M; Takeo M; Iwasa M; Ikoma J; Watanabe S; Adachi Y
    Am J Gastroenterol; 2003 Mar; 98(3):645-52. PubMed ID: 12650801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
    Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
    J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.
    Knolle PA; Kremp S; Höhler T; Krummenauer F; Schirmacher P; Gerken G
    J Viral Hepat; 1998 Nov; 5(6):399-406. PubMed ID: 9857349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
    Fujita N; Kaito M; Tanaka H; Horiike S; Urawa N; Sugimoto R; Konishi M; Watanabe S; Adachi Y
    J Viral Hepat; 2006 Mar; 13(3):190-8. PubMed ID: 16475995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy.
    Izopet J; Payen JL; Alric L; Sandres K; Charlet JP; Vinel JP; Duffaut M; Pascal JP; Puel J
    J Med Virol; 1998 Feb; 54(2):86-91. PubMed ID: 9496364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
    Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
    Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Miyazaki K; Kuwata Y; Yamazaki K; Sato T; Ohmura T; Matsushima T
    J Gastroenterol Hepatol; 2003 Apr; 18(4):404-10. PubMed ID: 12653888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group.
    Lee WM; Reddy KR; Tong MJ; Black M; van Leeuwen DJ; Hollinger FB; Mullen KD; Pimstone N; Albert D; Gardner S
    Hepatology; 1998 Nov; 28(5):1411-5. PubMed ID: 9794929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HCV RNA titer at the end of interferon therapy predicts the long-term outcome of treatment.
    Aiyama T; Yoshioka K; Takayanagi M; Iwata K; Okumura A; Kakumu S
    J Hepatol; 1995 Nov; 23(5):497-502. PubMed ID: 8583135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
    Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
    Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.
    McHutchison JG; Shad JA; Gordon SC; Morgan TR; Ling MH; Garaud JJ; Albrecht JK; Dienstag JL
    J Viral Hepat; 2001 Nov; 8(6):414-20. PubMed ID: 11703572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group.
    Keeffe EB; Dusheiko GM; Tong MJ; Hollinger FB; Heathcote EJ; McHutchison J; Albert D
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):211-6. PubMed ID: 10850385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course.
    Arase Y; Ikeda K; Chayama K; Murashima N; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Kumada H
    J Gastroenterol; 2000; 35(8):607-12. PubMed ID: 10955599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is early virological response as predictive of the hepatitis C treatment response in dialysis patients as in non-uremic patients?
    Fucuta Pereira Pda S; Uehara SN; de Mello Perez R; Feldner AC; de Melo IC; de Souza e Silva IS; Silva AE; Ferraz ML
    Int J Infect Dis; 2013 Jan; 17(1):e50-3. PubMed ID: 23041364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: a predictive marker for IFN therapy.
    Akiyoshi F; Sata M; Uchimura Y; Suzuki H; Tanikawa K
    Am J Gastroenterol; 1997 Sep; 92(9):1463-6. PubMed ID: 9317063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.